Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARCH 2: Abemaciclib + Fulvestrant in HR+, HER2- Advanced Breast Cancer
NCT02107703Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival at 31 months. Started Jul 2014; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02107703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107703.